GPR55 and Parkinson disease: A 6-hydroxydopamine-induced rat PD model showed reduced sensorimotor and motor functions, which were prevented by intrastriatal administration of the GPR55 agonist lysophosphatidylinositol (LPI), as well as the antagonist ML-193, suggesting a modulatory role of GPR55 in PD [83].